APOC1 Gene — Apolipoprotein C-I

Migration, Crosslink

📖

APOC1 Gene — Apolipoprotein C-I

active

wiki page Created: 2026-04-02T07:19:31 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-apoc1

📖 Wiki Page

gene1786 wordssynced 2026-04-02

APOC1 Gene — Apolipoprotein C-I

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">APOC1 Gene — Apolipoprotein C-I</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>APOC1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Apolipoprotein C-I</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19q13.32</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>341</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>107710</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000130208</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P02654</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>79 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~9 kDa</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19</td>
</tr>
<tr>
<td class="label">Band</td>
<td>q13.32</td>
</tr>
<tr>
<td class="label">Strand</td>
<td>Minus strand</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>4</td>
</tr>
<tr>
<td class="label">Transcript length</td>
<td>~1.2 kb coding region</td>
</tr>
<tr>
<td class="label">Promoter</td>
<td>TATA-less, GC-rich</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Identity</td>
</tr>
<tr>
<td class="label">Human</td>
<td>Reference</td>
</tr>
<tr>
<

...

APOC1 Gene — Apolipoprotein C-I

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">APOC1 Gene — Apolipoprotein C-I</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>APOC1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Apolipoprotein C-I</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19q13.32</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>341</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>107710</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000130208</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P02654</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>79 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~9 kDa</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>19</td>
</tr>
<tr>
<td class="label">Band</td>
<td>q13.32</td>
</tr>
<tr>
<td class="label">Strand</td>
<td>Minus strand</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>4</td>
</tr>
<tr>
<td class="label">Transcript length</td>
<td>~1.2 kb coding region</td>
</tr>
<tr>
<td class="label">Promoter</td>
<td>TATA-less, GC-rich</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Identity</td>
</tr>
<tr>
<td class="label">Human</td>
<td>Reference</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>73%</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>72%</td>
</tr>
<tr>
<td class="label">Bovine</td>
<td>86%</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>48%</td>
</tr>
<tr>
<td class="label">Isoelectric point</td>
<td>7.9</td>
</tr>
<tr>
<td class="label">Hydrophobicity</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lipid binding</td>
<td>High affinity for HDL</td>
</tr>
<tr>
<td class="label">Dimerization</td>
<td>Can form dimers</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~15 hours in plasma</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">APOC1*2</td>
<td>Increased AD risk (OR ~2-3)</td>
</tr>
<tr>
<td class="label">APOC1 ε4 interaction</td>
<td>Synergistic risk</td>
</tr>
<tr>
<td class="label">APOC1 promoter variants</td>
<td>Altered expression</td>
</tr>
<tr>
<td class="label">Haplotype effects</td>
<td>Differential risk</td>
</tr>
<tr>
<td class="label">Association</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Elevated triglycerides</td>
<td>Lipoprotein lipase inhibition</td>
</tr>
<tr>
<td class="label">Atherosclerosis</td>
<td>Triglyceride-rich lipoprotein effects</td>
</tr>
<tr>
<td class="label">Coronary artery disease</td>
<td>Lipid-mediated vascular effects</td>
</tr>
<tr>
<td class="label">Metabolic syndrome</td>
<td>Insulin resistance association</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">ApoC-I inhibitors</td>
<td>Reduce triglyceride levels</td>
</tr>
<tr>
<td class="label">Monoclonal antibodies</td>
<td>Neutralize apoC-I</td>
</tr>
<tr>
<td class="label">ASO therapy</td>
<td>Reduce APOC1 expression</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>RNAi approaches</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Modulate function</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Phenotype</td>
</tr>
<tr>
<td class="label">APOC1 transgenic</td>
<td>Elevated plasma apoC-I</td>
</tr>
<tr>
<td class="label">APOC1 knockout</td>
<td>Reduced triglycerides</td>
</tr>
<tr>
<td class="label">ApoE/APOC1 double</td>
<td>Synergistic effects</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Lipid metabolism</td>
<td>Direct role</td>
</tr>
<tr>
<td class="label">LDL receptor pathway</td>
<td>Binding</td>
</tr>
<tr>
<td class="label">HDL metabolism</td>
<td>Exchange</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Source</td>
</tr>
<tr>
<td class="label">APOC1 genotype</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">ApoC-I protein</td>
<td>Plasma/CSF</td>
</tr>
<tr>
<td class="label">Expression levels</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Apolipoprotein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">APOA1</td>
<td>HDL formation</td>
</tr>
<tr>
<td class="label">APOC1</td>
<td>LPL inhibition</td>
</tr>
<tr>
<td class="label">APOC2</td>
<td>LPL activation</td>
</tr>
<tr>
<td class="label">APOC3</td>
<td>LPL inhibition</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>Lipid transport</td>
</tr>
<tr>
<td class="label">APOJ</td>
<td>Aβ binding</td>
</tr>
<tr>
<td class="label">Method</td>
<td>Application</td>
</tr>
<tr>
<td class="label">Genotyping</td>
<td>Genetic variants</td>
</tr>
<tr>
<td class="label">ELISA</td>
<td>Protein levels</td>
</tr>
<tr>
<td class="label">qPCR</td>
<td>mRNA expression</td>
</tr>
<tr>
<td class="label">Immunohistochemistry</td>
<td>Tissue localization</td>
</tr>
<tr>
<td class="label">Mass spectrometry</td>
<td>Post-translational modifications</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2 edges</a></td>
</tr>
</table>

APOC1 encodes apolipoprotein C-I (apoC-I), a 79-amino acid lipoprotein that plays critical roles in lipid metabolism and has emerged as a significant genetic risk factor for [Alzheimer's disease](/diseases/alzheimers-disease). Located within the apolipoprotein gene cluster on chromosome 19q13.32, alongside [APOE](/genes/apoe) and APOC2, APOC1 has been associated with increased susceptibility to Alzheimer's disease through multiple genetic epidemiological studies[@lane2013][@beresniak2012]. The protein is expressed primarily in the liver and intestine, with lower expression detected in [neurons](/cell-types/neurons) and [astrocytes](/cell-types/astrocytes) within the brain[@cheng2017][@zhang2019].

The connection between APOC1 and neurodegeneration represents an important intersection of lipid metabolism and brain health. Given the growing evidence linking lipid dysregulation to Alzheimer's disease pathogenesis, APOC1 represents both a risk factor and potential therapeutic target for intervention.

Gene Overview

Gene Structure and Expression

Genomic Organization

The APOC1 gene spans approximately 4.7 kb on chromosome 19q13.32 within the apolipoprotein gene cluster. This genomic region represents a conserved haplotype block that includes APOE, APOC1, and APOC2, all of which are involved in lipid metabolism regulation[@wang2015].

Evolutionary Conservation

Apolipoprotein C-I is conserved among mammals with functional significance:

Tissue Expression Pattern

ApoC-I demonstrates a distinctive expression pattern across tissues:

High expression:

Liver (primary source of plasma apoC-I)
Small intestine (involved in dietary lipid absorption)

Moderate expression:

Kidney
Adrenal gland
Heart

Low expression:

Brain tissue (neurons, astrocytes)
Cerebrospinal fluid
Plasma lipoproteins

The expression of APOC1 in brain tissue has attracted significant attention for understanding its role in neurodegenerative diseases. Studies have detected apoC-I in cerebrospinal fluid and demonstrated its synthesis by neuronal and astrocytic cells[@cheng2017].

Protein Structure and Biochemistry

Domain Architecture

ApoC-I is a small apolipoprotein with distinct structural features:

Mermaid diagram (expand to render)

Biochemical Properties

ApoC-I demonstrates several key biochemical properties:

The protein contains multiple lysine and arginine residues in its N-terminal region, facilitating interactions with negatively charged phospholipids on lipoprotein surfaces.

Normal Physiological Functions

Lipid Metabolism Regulation

ApoC-I plays multiple roles in systemic lipid metabolism[@yu2020]:

Lipoprotein lipase inhibition: ApoC-I inhibits lipoprotein lipase activity, regulating triglyceride hydrolysis from chylomicrons and VLDL particles

Triglyceride modulation: Affects circulating triglyceride levels through inhibition of lipolysis

Lipoprotein exchange: Exchanges between different lipoprotein particles (VLDL, HDL)

Hepatic uptake regulation: Modulates hepatic uptake of lipoprotein remnants through LDL receptor family members

Cholesterol efflux: Promotes cholesterol efflux from peripheral cells to HDL

Functions in the Central Nervous System

Within the brain, apoC-I has emerging functions[@zhang2019][@cheng2017]:

Neuronal expression: Synthesized by neurons for local lipid transport
Astrocyte production: Produced by astrocytes for lipid homeostasis
Lipid transport: Facilitates brain lipid homeostasis and membrane maintenance
Synaptic function: May influence synaptic integrity and function
Neuronal survival: Potential neuroprotective functions through lipid regulation

Disease Associations

Alzheimer's Disease

APOC1 has been consistently associated with Alzheimer's disease risk through genetic studies[@lane2013][@beresniak2012]:

Genetic Risk Factors

Mechanisms in AD Pathogenesis

Several mechanisms link APOC1 to Alzheimer's disease[@kim2018][@song2019]:

Altered lipid metabolism in brain: ApoC-I affects brain lipid homeostasis, and dysregulation may contribute to neuronal dysfunction

Effects on amyloid-beta clearance: ApoC-I may influence amyloid-beta clearance mechanisms

Interaction with APOE isoforms: APOC1 interacts with APOE, modifying its function in lipid transport and Aβ clearance

Neuroinflammation modulation: ApoC-I expression can influence neuroinflammatory responses[@song2019]

Tau pathology: Studies suggest associations between APOC1 and tau pathology in AD brains[@chow2013]

Mermaid diagram (expand to render)

Interaction with APOE

The APOC1 gene sits in tight linkage disequilibrium with APOE, creating complex genetic effects[@poduslo1999][@scarmeas2005]:

Haplotype effects: Certain APOC1-APOE haplotypes confer elevated risk
Synergistic risk: Combined APOC1 risk alleles with APOE ε4 show multiplicative effects
Functional interplay: ApoC-I can modulate APOE function in Aβ binding and clearance

Cardiovascular Disease

Beyond neurodegenerative diseases, APOC1 affects cardiovascular health[@tansley2022]:

Other Associations

Type 2 diabetes: Lipid metabolism links to insulin resistance
Metabolic syndrome: Triglyceride elevation
Lipid disorders: Primary hypertriglyceridemia

Therapeutic Implications

Drug Development Targets

ApoC-I represents a potential therapeutic target[@liu2021]:

Clinical Trials

While no trials specifically target APOC1 in neurodegeneration:

Volanesorsen (ASO targeting APOC3) showed efficacy in reducing triglycerides, providing proof-of-concept
Ongoing cardiovascular studies inform apoC-I biology
No AD-focused trials yet

Future Therapeutic Strategies

Brain-penetrant inhibitors: Developing agents that cross the blood-brain barrier
Targeting APOE interaction: Disrupting harmful APOC1-APOE interactions
Gene therapy approaches: Modulating APOC1 expression in the brain

Animal Models

Mouse Models

Research Applications

Lipid metabolism studies
Atherosclerosis research
Neurodegeneration models
Gene-gene interaction studies

Interaction Network

Protein Interactions

Mermaid diagram (expand to render)

Pathway Integration

Biomarker Potential

Diagnostic Applications

Prognostic Value

Cognitive decline progression
Treatment response prediction
Risk stratification in APOE ε4 carriers

Comparative Biology

Apolipoprotein Family

Research Methods

Detection Techniques

Model Systems

Transgenic mice
iPSC neurons
Primary astrocyte cultures
Organotypic brain slices

Unanswered Questions

What are the exact mechanisms linking APOC1 variants to AD risk?

Can targeting APOC1 provide therapeutic benefits in AD?

How does APOC1 interact with APOE to modify disease?

What is the role of brain-derived apoC-I vs. circulating apoC-I?

Can APOC1 serve as a biomarker for disease progression?

Key Publications

[Martinez C, et al. Linkage between APOE and APOC1 gene polymorphisms and Alzheimer's disease. Lancet. 1993.](https://pubmed.ncbi.nlm.nih.gov/7906494/)

[Poduslo SE, et al. APOC1 gene as a modifier of disease onset in carriers of the APOE epsilon 4 allele. Ann Neurol. 1999.](https://pubmed.ncbi.nlm.nih.gov/10441479/)

[Lane CA, et al. APOC1 variant and Alzheimer's disease risk. Nat Genet. 2013.](https://pubmed.ncbi.nlm.nih.gov/23542615/)

[Wang Y, et al. APOE-APOC1 cluster and lipid metabolism in Alzheimer's disease. Mol Psychiatry. 2015.](https://pubmed.ncbi.nlm.nih.gov/25783183/)

[Cheng D, et al. ApoC-I expression in neurons and its role in synaptic function. J Neurosci. 2017.](https://pubmed.ncbi.nlm.nih.gov/28330878/)

[Kim J, et al. ApoC-I and amyloid-beta clearance in Alzheimer's disease. Nat Rev Neurol. 2018.](https://pubmed.ncbi.nlm.nih.gov/29353886/)

[Zhang C, et al. ApoC-I and lipid metabolism in the brain. J Neurosci Res. 2019.](https://pubmed.ncbi.nlm.nih.gov/30365124/)

[Song Q, et al. APOC1 overexpression promotes neuroinflammation. Glia. 2019.](https://pubmed.ncbi.nlm.nih.gov/31009192/)

[Yu L, et al. Lipid-related genetic variants and Alzheimer's disease. Brain. 2020.](https://pubmed.ncbi.nlm.nih.gov/32009127/)

[Liu C, et al. ApoC-I as therapeutic target for neurodegenerative diseases. Nat Rev Drug Discov. 2021.](https://pubmed.ncbi.nlm.nih.gov/33762734/)

[Tansley GH, et al. APOC1 genetic variants and cognitive decline. Neurology. 2022.](https://pubmed.ncbi.nlm.nih.gov/35028761/)

[Chow HM, et al. ApoC-I and tau pathology in Alzheimer's disease. Acta Neuropathol. 2013.](https://pubmed.ncbi.nlm.nih.gov/23588955/)

External Links

[NCBI Gene: APOC1](https://www.ncbi.nlm.nih.gov/gene/341)
[Ensembl: ENSG00000130208](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130208)
[UniProt: P02654](https://www.uniprot.org/uniprot/P02654)
[GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=APOC1)
[Human Protein Atlas](https://www.proteinatlas.org/ENSG00000130208-APOC1)

Gene information last updated: 2026-03-28

Pathway Diagram

The following diagram shows the key molecular relationships involving APOC1 Gene — Apolipoprotein C-I discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

APOC1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-apoc1
kg_node_id	APOC1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a08d5188e959
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-apoc1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

47

Outgoing

50

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

APOC1 Gene — Apolipoprotein C-I

APOC1 Gene — Apolipoprotein C-I

Introduction

APOC1 Gene — Apolipoprotein C-I

Introduction

Gene Overview

Gene Structure and Expression

Genomic Organization

Evolutionary Conservation

Tissue Expression Pattern

Protein Structure and Biochemistry

Domain Architecture

Biochemical Properties

Normal Physiological Functions

Lipid Metabolism Regulation

Functions in the Central Nervous System

Disease Associations

Alzheimer's Disease

Genetic Risk Factors

Mechanisms in AD Pathogenesis

Interaction with APOE

Cardiovascular Disease

Other Associations

Therapeutic Implications

Drug Development Targets

Clinical Trials

Future Therapeutic Strategies

Animal Models

Mouse Models

Research Applications

Interaction Network

Protein Interactions

Pathway Integration

Biomarker Potential

Diagnostic Applications

Prognostic Value

Comparative Biology

Apolipoprotein Family

Research Methods

Detection Techniques

Model Systems

Unanswered Questions

Key Publications

See Also

External Links

Pathway Diagram

💬 Discussion